In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

USA: A new study published in the Journal of Diabetes and Its Complications suggests that tirzepatide, a novel dual ...

A recent study published in the Journal of the American Dental Association found that Tirzepatide presented a novel strategy ...

WEDNESDAY, March 19, 2025 (HealthDay News) -- Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study published online March 14 in JAMA Health ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

MPC-inhibitor 0602K shows significant preservation of lean mass & increased muscle function combined with tirzepatide in pre-clinical DIO models0602K shows profound beneficial transformation ...

Prices are falling for the popular obesity treatments semaglutide (Wegovy) and tirzepatide (Zepbound), but steady access to ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction, according to a study published online June 24 ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, ...

Cirius Therapeutics shares promising results of MPC Inhibitor 0602K, used alone or with Tirzepatide, highlighting advancements in therapeutic treatments.